AC
ACW.AU Actinogen Medical Ltd
- Market cap
- AUD 163M
- P/E
- -
- P/B
- 7.61x
- ROE
- -72.0%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is ACW.AU undervalued?
Graham numberThe Graham number of Actinogen Medical Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Actinogen Medical Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-72.0%), below 10%.
ROA 0/1
Return on assets (-52.0%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (6.6%) is above the industry median (-5.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (22.4%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 1.0 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (7.6x) is above the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Actinogen Medical Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Actinogen Medical Ltd
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and cha…
Full company profileActinogen Medical Ltd financial statements
Actinogen Medical Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.42M | 3.30M | 4.86M | 3.52M | 1.98M | 3.64M | 4.89M | 9.93M | 5.49M | - |
| Gross Profit | 1.05M | 2.94M | 4.51M | 3.10M | 1.60M | 3.24M | 4.48M | 9.93M | 5.49M | -419K |
| Operating Income | -4.60M | -9.56M | -9.61M | -8.91M | -5.90M | -13.2M | -15.9M | -12.8M | -14.9M | -28.1M |
| EBITDA | -2.82M | -5.91M | -9.25M | -8.20M | -5.35M | -12.7M | -15.2M | -12.8M | -14.9M | -27.7M |
| Net Income | -3.19M | -6.23M | -9.89M | -5.33M | -3.92M | -9.50M | -10.8M | -13.0M | -14.7M | -15.4M |
| EPS | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 10.2M | 18.0M | 16.2M | 11.9M | 18.4M | 23.3M | 15.2M | 21.3M | 24.5M | 29.6M |
| Total Liabilities | 844K | 768K | 557K | 1.05M | 920K | 1.57M | 1.80M | 1.62M | 6.15M | 8.18M |
| Shareholders' Equity | 9.37M | 17.3M | 15.7M | 10.9M | 17.5M | 21.7M | 13.4M | 19.7M | 18.3M | 21.4M |
| Cash & Short-term Investments | 3.99M | 9.90M | 7.64M | 5.04M | 13.4M | 16.4M | 8.46M | 9.45M | 16.5M | 16.7M |
| Total Debt | - | - | 390K | 390K | 236K | 165K | 86.9K | 319K | 3.26M | 4.78M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.11M | -7.91M | -10.5M | -2.86M | -1.72M | -9.52M | -8.70M | -17.0M | -7.56M | -17.6M |
| Capital Expenditure | 1.03K | 274.00 | 22.8K | 22.8K | 6.19K | 2.94K | 36.6K | 8.16K | 38.0K | 9.29K |
| Free Cash Flow | -1.11M | -7.91M | -10.5M | -2.88M | -1.73M | -9.52M | -8.73M | -17.0M | -7.59M | -17.6M |
| Ratios | ||||||||||
| ROE | -34.1% | -36.1% | -63.1% | -49.0% | -22.4% | -43.7% | -80.2% | -66.2% | -80.3% | -72.0% |
| ROA | -31.2% | -34.6% | -61.0% | -44.7% | -21.3% | -40.8% | -70.7% | -61.2% | -60.2% | -52.0% |
| Net Profit Margin | -225.4% | -188.8% | -203.3% | -151.6% | -197.3% | -260.9% | -220.0% | -131.3% | -268.4% | - |
| Debt to Equity | - | - | 0.02x | 0.04x | 0.01x | 0.01x | 0.01x | 0.02x | 0.18x | 0.22x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Actinogen Medical Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 6.67K | 0.00 | - |
| 2022 | AUD 11.6M | 0.01 | - |
| 2021 | AUD 360K | 0.00 | - |
| 2020 | AUD 10.2M | 0.01 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:2 on Dec 3, 2013.
Who owns Actinogen Medical Ltd
- Insiders 22.02%
- Institutions 2.86%
- Public & others 75.12%
- Shares outstanding 3.87B
- Free float 3.12B
Actinogen Medical Ltd company profile
- Company name
- Actinogen Medical Ltd
- Ticker
- ACW.AU
- ISIN
- AU000000ACW3
- Exchange
- Australian Securities Exchange
- Listed since
- Oct 15, 2007
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 109 Pitt Street, Sydney, NSW, Australia, 2000
- Phone
- 61 2 8964 7401
- Website
- actinogen.com.au
About Actinogen Medical Ltd
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Actinogen Medical Ltd management
8- Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.MD, CEO & Director · born 1959
- Mr. William Edward Souter BCom, IPAA, LLB (Adel)Chief Financial Officer
- Dr. Dana C. Hilt M.D.Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board · born 1953
- Mr. Andrew B. Udell B.Sc., M.B.A.Chief Commercial Officer · born 1970
- Mr. Michael RobertsHead of Investor Relations & Corporate Communications
- Prof. Paul Edward Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.Head of Clinical Pharmacology & Lead Physician and Depression · born 1956
- Dr. Fujun Li Ph.D.Head of Manufacturing
- Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary · born 1963